Atlas Trials

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

Clinical trial NCT04833114 · COMPLETED

Trial details

NCT number
NCT04833114
Sponsor
GWT-TUD GmbH
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed Diffuse Large B-cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2021-04-30
Primary completion
2025-12-19
Enrollment
306

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.